The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed

Overview

Journal J Gastrointest Cancer

Publisher Springer

Specialties Gastroenterology
Oncology

Date 2017 Apr 12

PMID 28397102

Citations 5

Authors

Jorge Hernando-Cubero

Ignacio Matos-Garcia

Vicente Alonso-Orduna

Jaume Capdevila

Affiliations

Soon will be listed here.

Abstract

Purpose: Gastrointestinal tumours are one of the most common types of cancer. Therapeutic options include surgery, radiotherapy, local ablation techniques, targeted agents, and chemotherapy. Fluoroprimidines are one of the most active drug families in digestive tumours and remains the cornerstone of the most commonly used chemotherapy schemes.

Methods: We review the molecular basis of thymidylate synthase inhibition and the mechanisms of action of 5-fluorouracil, next generation oral fluoropyrimidines (capecitabine, tegafur and the latest S-1 and TAS-102) and antifolates.

Results: In addition, mechanisms and biomarkers of resistance and toxicity are explored. Finally, new fluoropyrimidines development and clinical trials ongoing in digestive tumours are reviewed.

Conclusions: Further research is necessary to avoid resistance mechanisms, improve clinical outcomes and continue reducing toxicities. Until new drugs become available, the optimization of current therapies should be a priority.

Citing Articles

Combination Therapy as a Promising Way to Fight Oral Cancer.

Silva J, Pinto B, Monteiro L, Silva P, Bousbaa H Pharmaceutics. 2023; 15(6).

PMID: 37376101 PMC: 10301495. DOI: 10.3390/pharmaceutics15061653.

Pharmacogenomic-guided dosing of fluoropyrimidines beyond : time for a polygenic algorithm?.

Maslarinou A, Manolopoulos V, Ragia G Front Pharmacol. 2023; 14:1184523.

PMID: 37256234 PMC: 10226670. DOI: 10.3389/fphar.2023.1184523.

Evaluation of TS and ENOSF1 Variants as a Biomarker in Response to Neoadjuvant Chemotherapy based on 5FU in Gastric Cancer Patients.

Arjmandi K, Ameli F, Salahshourifar I, Esfandbod M, Irani S Asian Pac J Cancer Prev. 2022; 23(9):2983-2989.

PMID: 36172660 PMC: 9810307. DOI: 10.31557/APJCP.2022.23.9.2983.

SAHA Overcomes 5-FU Resistance in IFIT2-Depleted Oral Squamous Cell Carcinoma Cells.

Regmi P, Lai K, Liu C, Lee T Cancers (Basel). 2020; 12(12).

PMID: 33256074 PMC: 7761248. DOI: 10.3390/cancers12123527.

[Expression of thymidylate synthase in salivary adenoid myoepithelial cells and its clinical significance].

Guo R, Tian Y, Zhu M, Huang Y, Qiang L, Jin X Nan Fang Yi Ke Da Xue Xue Bao. 2020; 40(4):469-474.

PMID: 32895123 PMC: 7225106. DOI: 10.12122/j.issn.1673-4254.2020.04.04.

References

Meulendijks D, Dewit L, Tomasoa N, van Tinteren H, Beijnen J, Schellens J . Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer. 2014; 111(9):1726-33. PMC: 4453727. DOI: 10.1038/bjc.2014.467. View

Yen-Revollo J, Goldberg R, McLeod H . Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?. Clin Cancer Res. 2008; 14(1):8-13. DOI: 10.1158/1078-0432.CCR-07-1225. View

Jackman A, Gibson W, Brown M, Kimbell R, Boyle F . The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. Adv Exp Med Biol. 1993; 339:265-76. DOI: 10.1007/978-1-4615-2488-5_26. View

Kim S, Hong Y, Lim H, Lee J, Kim T, Kim K . S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. BMC Cancer. 2014; 14:883. PMC: 4289339. DOI: 10.1186/1471-2407-14-883. View

Gravalos C, Salut A, Garcia-Giron C, Garcia-Carbonero R, Leon A, Sevilla I . A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. Clin Transl Oncol. 2012; 14(8):606-12. PMC: 3427491. DOI: 10.1007/s12094-012-0843-x. View

Piedbois P, Rougier P, Buyse M, Pignon J, Ryan L, Hansen R . Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998; 16(1):301-8. DOI: 10.1200/JCO.1998.16.1.301. View

Sobrero A, Guglielmi A, Grossi F, Puglisi F, Aschele C . Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy. Semin Oncol. 2000; 27(5 Suppl 10):72-7. View

Mullany S, Svingen P, Kaufmann S, Erlichman C . Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol. 1998; 42(5):391-9. DOI: 10.1007/s002800050835. View

Alcindor T, Beauger N . Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol. 2011; 18(1):18-25. PMC: 3031353. DOI: 10.3747/co.v18i1.708. View

10.

Berlin J, Catalano P, Thomas J, Kugler J, Haller D, Benson 3rd A . Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002; 20(15):3270-5. DOI: 10.1200/JCO.2002.11.149. View

11.

Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F . Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358(1):36-46. DOI: 10.1056/NEJMoa073149. View

12.

Twelves C . Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. Clin Colorectal Cancer. 2007; 6(4):278-87. DOI: 10.3816/CCC.2006.n.046. View

13.

Schmoll H, Tabernero J, Maroun J, De Braud F, Price T, Van Cutsem E . Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. J Clin Oncol. 2015; 33(32):3733-40. DOI: 10.1200/JCO.2015.60.9107. View

14.

Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M . Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001; 19(21):4097-106. DOI: 10.1200/JCO.2001.19.21.4097. View

15.

Sohn K, Croxford R, Yates Z, Lucock M, Kim Y . Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst. 2004; 96(2):134-44. DOI: 10.1093/jnci/djh015. View

16.

Louvet C, De Gramont A . Pemetrexed in advanced colorectal cancer. Oncology (Williston Park). 2005; 18(13 Suppl 8):56-62. View

17.

Kelly C, Bhuva N, Harrison M, Buckley A, Saunders M . Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. Eur J Cancer. 2013; 49(10):2303-10. DOI: 10.1016/j.ejca.2013.03.004. View

18.

Brynolf K, Eliasson R, REICHARD P . Formation of Okazaki fragments in polyoma DNA synthesis caused by misincorporation of uracil. Cell. 1978; 13(3):573-80. DOI: 10.1016/0092-8674(78)90330-6. View

19.

Mayer R, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N . Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015; 372(20):1909-19. DOI: 10.1056/NEJMoa1414325. View

20.

COCCONI G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, Van Hazel G . Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol. 1998; 16(9):2943-52. DOI: 10.1200/JCO.1998.16.9.2943. View